Carefully crafted to provide tightly focused and authoritative information, the Directory of Therapeutic Enzymes covers all approved therapeutic enzymes currently used in medicine. Written mainly by industry experts, the book includes information sourced directly from the company that developed or manufactured the product. It explores major development issues, from manufacturing and marketing to delivery of the finished product. Chapter 1 reviews applied enzymology while chapter 2 delineates theory and applications. Between them, the first two chapters set the appropriate backdrop for the remaining chapters, which focus on actual enzyme products that have gained regulatory approval for general medical use. The chapter authors discuss the biochemistry of the enzymes, the reactions they catalyze, how they are produced or manufactured, and their medical applications. The book highlights the many applications of approved therapeutic enzymes, including use in the treatment of blood-clotting disorders, certain cancers, and a variety of genetic disorders. Illustrated with tables and figures that support the text, the book is a single source of in-depth technical information.

Emphasizing its uses in cancer and cardiovascular and autoimmune diseases, Pharmaceutical Perspectives of Nucleic Acid-Based Therapy presents a comprehensive account of gene therapy, from development in the laboratory to clinical applications. Internationally acclaimed scientists discuss the potential use of lipids, peptides and polymers for the in vivo delivery of nucleic acids, the genesis of structure-synthesis-function interrelationships and the evolutionary approaches of these gene carriers. The book also addresses the influence of a viable gene expression system on disease by controlling gene regulation, transcription, translation and replication.

DHEA and the Brain reviews a range of existing studies regarding DHEA administration to animals and humans. Chapter authors evaluate DHEA metabolism in tissues and organs, explore DHEA effects in the liver that may be of importance to the brain, and discuss recent findings regarding how DHEA is made in the brain. New perspectives about the neuroprotective effects of DHEA are presented, as well as insight related to DHEA metabolism in the brain. A number of health benefits have been associated with dehydroepiandrosterone (DHEA), including anti-cancer, anti-osteoporosis, anti-atherosclerosis, anti-diabetes, immuno-stimulating, and memory-enhancing effects. This has prompted millions of people to take this hormone as a daily nutritional supplement. However, there is some concern that prolonged self-administration may result in future health problems, as well as unease about potential side effects due to the production of steroid derivatives in the tissues. Featuring an esteemed panel of contributors, this volume provides an authoritative overview of the research concerning DHEA and the brain. It presents a variety of innovative approaches and ideas for future investigations into the physiological actions of this hormone.

Inhalation aerosols continue to be the basis for successful lung therapy for several diseases, with therapeutic strategies and the range of technology significantly evolving in recent years. In response, this third edition takes a new approach to reflect the close integration of technology with its application. After briefly presenting the general considerations that apply to aerosol inhalation, the central section of the book uses the focus on disease and therapeutic agents to illustrate the application of specific technologies. The final integrated strategies section draws the major points from the applications for disease targets and drug products.

Medicinal Chemistry: A Look at How Drugs Are Discovered is written for those who are interested in learning how drugs are discovered. Compared to other books on the market, this text takes a different approach by presenting the subject on chemical reaction mechanism terms, which ideally makes the subject matter more interesting and easier to comprehend. The authors describe the drug discovery process, from advancing an initial lead to the approval process, and include drug discovery sources. Additional features: Explains medicinal chemistry on chemical mechanism terms, allowing for a more interesting and easier to comprehend text Includes valuable insights toward the various pathways taken at pharmaceutical industries in drug discoveries Improved by including questions raised and suggestions made from students in the authors' medicinal chemistry classes This book will benefit both upper level undergraduates and graduates studying in the fields of medicinal chemistry and drug discovery, as well as scientists working in the pharmaceutical industry.

Describes the ways Vitamin C can inhibit, perturb or retard the growth and spread of cancer through changing the ways cancers respond to different doses and treatmentsSumarizes the results of clinical trialsOutlines therapeutical usesChapters by an international team of researchers.

"...a useful addition to the bookshelf of every natural material specialist..." -Pharmazie in unserer Zeit, 2010 (review in German) Organized in a classical alphabetical format, this two-volume reference covers 1000 carefully screened natural product structures. For each compound or compund class, a basic chemical characterization is given, followed by a description of the biological source and a discussion of their pharmaceutical potential as lead molecules for new drugs. The letter takes into account the documented uses of many of these compounds in Asian traditional medicine. By way of its clearly structured articles, and with the aid of classification tables in the appendix, this dictionary is easy to use and provides quick and reliable information for researchers as well for scholars and student. Compounds have been selected from the following chemical classes: - Alkaloids - Phenolics - Antibiotics - Polyketides - Carbohydrates - Proteins - Chalcones - Steroids - Coumarins - Terpenoids - Flavonoids - Xanthonoids - Peptides

Encapsulation of bioactives is a fast-growing approach in the food and pharmaceutical industry. Spray Drying Encapsulation of Bioactive Materials serves as a source of information to offer specialized and in-depth knowledge on the most well-known and used encapsulation technology (i.e., spray drying) and corresponding advances. It describes the efficacy of spray drying in terms of its advantages and challenges for encapsulation of bioactive ingredients. Discusses the potential of this technique to pave the way toward cost-effective, industrially relevant, reproducible, and scalable processes that are critical to the development of delivery systems for bioactive incorporation into innovative functional food products and pharmaceuticals Presents the latest research outcomes related to spray drying technology and the encapsulation of various bioactive materials Covers advances in spray drying technology that may result in a more efficient encapsulation of bioactive ingredients Includes computational fluid dynamics, advanced drying processes, as well as the morphology of the dried particles, drying kinetics analyzers, process controllers and adaptive feedback systems, inline powder analysis technologies, and cleaning-in-place equipment Aimed at food manufacturers, pharmacists, and chemical engineers, this work is of interest to anyone engaged in encapsulation of bioactive ingredients for both nutraceutical and pharmaceutical applications.

Parents in the US and other societies are increasingly refusing to vaccinate their children, even though popular anti-vaccine myths - e.g. 'vaccines cause autism' - have been debunked. This book explains the epistemic and moral failures that lead some parents to refuse to vaccinate their children. First, some parents have good reasons not to defer to the expertise of physicians, and to rely instead upon their own judgments about how to care for their children. Unfortunately, epistemic self-reliance systematically distorts beliefs in areas of inquiry in which expertise is required (like vaccine immunology). Second, vaccine refusers and mainstream medical authorities are often committed to different values surrounding health and safety. For example, while vaccine advocates stress that vaccines have low rates of serious complications, vaccine refusers often resist vaccination because it is 'unnatural' and because they view vaccine-preventable diseases as a 'natural' part of childhood. Finally, parents who refuse vaccines rightly resist the utilitarian moral arguments - 'for the greater good' - that vaccine advocates sometimes make. Unfortunately, vaccine refusers also sometimes embrace a pernicious hyper-individualism that sanctions free-riding on herd immunity and that cultivates indifference to the interpersonal and social harms that unvaccinated persons may cause.

Prescribing Mental Health Medication is a comprehensive text for all practitioners who treat mental disorders with medication. This new (third) edition is fully updated and includes a variety of additional chapters. Prescribing Mental Health Medication covers the latest digital methodologies including Internet-based mental health treatment, electronic medical records and prescriber use of social media. Including information on all psychotropic medications in use in the United States and the United Kingdom, the book incorporates clinical tips, sample dialogues for talking about mental health medications to patients, and information specifically relevant in primary care settings. It looks at: * how to determine if medication is needed, proper dosing and how to start, stop and change medication * specific mental health symptoms and appropriate medication * special populations including non-adherent patients, medication abusers, those mixing alcohol and psychotropics, confused patients, children, adolescents, pregnant women and seniors * management of medication side effects and avoidance of medication risk * prescription of generic preparations * organizing a prescriptive office and record keeping. The additional chapters in this new edition of Prescribing Mental Health Medication cover topics such as combining specific medications, combining medications and psychological therapies, use of 'natural' substances in mental health treatment, successfully managing patient relapse, and appropriate prescriptions of potentially controversial medications such as stimulants and benzodiazepines. This practical text explains the entire process of medication assessment, management and follow up for general medical practitioners, mental health practitioners, students, residents, prescribing nurses and others perfecting this skill.

Covers micro- and Nano- technologies approaches with current trends with safety and efficacy in product development. Presents overview of recent progress of stability testing, reverse engineering, validation and regulatory perspectives as per regulatory requirements. Provides comprehensive overview of latest research related to the micro and nanotechnological including designing, optimization, validation, scale of micro and nanotechnologies. This book is edited by the two-well known researchers by contribution of the vivid chapters from renowned scientists across the globe in field of pharmaceutical sciences.

Praise for the Second Edition: "... this is a useful, comprehensive compendium of almost every possible sample size formula. The strong organization and carefully defined formulae will aid any researcher designing a study." -Biometrics "This impressive book contains formulae for computing sample size in a wide range of settings. One-sample studies and two-sample comparisons for quantitative, binary, and time-to-event outcomes are covered comprehensively, with separate sample size formulae for testing equality, non-inferiority, and equivalence. Many less familiar topics are also covered ..." - Journal of the Royal Statistical Society Sample Size Calculations in Clinical Research, Third Edition presents statistical procedures for performing sample size calculations during various phases of clinical research and development. A comprehensive and unified presentation of statistical concepts and practical applications, this book includes a well-balanced summary of current and emerging clinical issues, regulatory requirements, and recently developed statistical methodologies for sample size calculation. Features: Compares the relative merits and disadvantages of statistical methods for sample size calculations Explains how the formulae and procedures for sample size calculations can be used in a variety of clinical research and development stages Presents real-world examples from several therapeutic areas, including cardiovascular medicine, the central nervous system, anti-infective medicine, oncology, and women's health Provides sample size calculations for dose response studies, microarray studies, and Bayesian approaches This new edition is updated throughout, includes many new sections, and five new chapters on emerging topics: two stage seamless adaptive designs, cluster randomized trial design, zero-inflated Poisson distribution, clinical trials with extremely low incidence rates, and clinical trial simulation.

Provides an understanding of (mostly) enzymatic reactions that are responsible for the function and maintenance of living things This innovative text for non-biochemistry majors includes introductory material at the beginning of each chapter that contextualizes chapter themes in real-life scenarios Online supporting materials with further opportunities for research and investigation Synthesis questions at the end of each chapter that encourage students to make connections between concepts and ideas, as well as develop critical-thinking skills

In Silico Drug Discovery and Design: Theory, Methods, Challenges, and Applications provides a comprehensive, unified, and in-depth overview of the current methodological strategies in computer-aided drug discovery and design. Its main aims are to introduce the theoretical framework and algorithms, discuss the range of validity, strengths and limitations of each methodology, and present applications to real world problems in the drug discovery arena. Special emphasis has been given to the emerging and most pressing methodological challenges in in silico drug discovery and design. The book assumes a basic knowledge of physical principles and molecular modeling. Particular attention has been paid to outline the underlying physico-chemical foundation of the methods described, thus providing the necessary background to avoid a "black-box" approach. In each self-contained chapter, this is presented together with the latest developments and applications, and the challenges that lie ahead. Assembling a unique team of experts to weigh in on the most important issues influencing modern computational drug discovery and design, this book constitutes both a desktop reference to academic and industrial researchers in the field, and a textbook for students in the area of molecular modeling and drug discovery. Comprised of 18 chapters and divided into three parts, this book: Provides a comprehensive, unified, and in-depth overview of the current methodological strategies in computer-aided drug discovery and design Outlines the underlying physico-chemical foundation of the methods described Presents several applications of computational methods to real world problems in the drug design field Helps to avoid a "black-box" approach to in silico drug discovery Constitutes an actual textbook for students in the area of molecular modeling and drug discovery Gives the reader the adequate background to face the current challenges of the field In Silico Drug Discovery and Design: Theory, Methods, Challenges, and Applications describes the theoretical framework, methods, practical applications and case examples relevant to computer-aided drug lead discovery and design. This text will surely aid in understanding the underlying physical foundation of computational tools and their range of application, thus facilitating the interpretation of simulation results.

First published in 1999. This comprehensive neuropsychotropic drug reference is designed with prescribing psychologists and psychology students in mind. An accurate and authoritative reference, the Psychologists' Neuropsychotropic Drug Reference (PNDR) details drug monographs for over 80 different prescription neuropsychotropic drugs available for clinical prescription in North America. Each neuropsychotropic monograph is clearly and concisely written to reflect essential and important data that are commonly required by prescribing psychologists and psychology students. Thus, whenever possible and appropriate, each monograph includes: a phonetic pronunciation guide; up to five common trade or brand names; pharmacologic or therapeutic classification and subclassification; USDEA schedule designation for abuse potential; recommended dosages; and many other critical details. The form, style, and content of each monograph has been reviewed by members of an Editorial Advisory Committee of distinguished psychologists. With this quality assurance, this text is certain to become an asset to prescribing psychologists and psychology students as they strive to provide the maximum benefit of neuropsychotropic pharmacotherapy.

This new volume, Promising Drug Molecules of Natural Origin, explores potential beneficial drug substances derived from nature. It presents the general principles, characteristics, evaluation techniques, and applications involved in drug molecules from natural sources, such as plants and marine life. With chapters from renowned experts from around the world, the chapters in this volume address the challenges of standardization of herbal medicines, methods of characterization of natural medicines and phyto-constituents, and quality control methods for herbal medicines. Several chapters in the book focus on the evolution of phyto-constituents in cancer therapeutics, while others deal with applications for other diseases, such as diabetes and neuroinflammatory disorders. The volume also specifically reviews heterocyclic drugs from plants. This volume will be a valuable resource for faculty and advanced students in pharmaceutics as well as researchers, scientists, and industry professionals in medicine and drug development.

Is adaptive randomization always better than traditional fixed-schedule randomization? Which procedures should be used and under which circumstances? What special considerations are required for adaptive randomized trials? What kind of statistical inference should be used to achieve valid and unbiased treatment comparisons following adaptive randomization designs? Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects answers these questions and more. From novel designs to cutting-edge applications, this book presents several new and key developments in adaptive randomization. It also offers a fresh and critical look at a number of already-classical topics. Featuring contributions from statisticians, clinical trialists, and subject-matter experts in academia and the pharmaceutical industry, the text: Clarifies the taxonomy of the concept of adaptive randomization Discusses restricted, covariate-adaptive, response-adaptive, and covariate-adjusted response-adaptive (CARA) randomization designs, as well as randomized designs with treatment selection Gives an exposition to many novel adaptive randomization techniques such as brick tunnel randomization, targeted least absolute shrinkage and selection operator (LASSO)-based CARA randomization, multi-arm multi-stage (MAMS) designs, to name a few Addresses the issues of statistical inference following covariate-adaptive and response-adaptive randomization designs Describes a successful implementation of a single pivotal phase II/III adaptive trial in infants with proliferating hemangioma Explores some practical aspects of phase II dose-ranging studies and examines statistical monitoring and interim analysis issues in response-adaptive randomized clinical trials Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects covers a wide spectrum of topics related to adaptive randomization designs in contemporary clinical trials. The book provides a thorough exploration of the merits of adaptive randomization and aids in identifying when it is appropriate to apply such designs in practice.

Treating Disruptive Disorders is a practical book for busy clinicians-psychiatrists, psychologists, mental health counselors, clinical social workers, and more-as well as students, interns, or residents in the mental health professions. It distills the most important information about combined as well as solitary treatments of a variety of psychological disorders characterized by disruptive behaviors, including those where disruptive aspects are part of core symptoms (like ADHD, ODD, or conduct disorder), and those where disruptive features are commonly associated with core symptoms (like mood, personality, and cognitive/developmental disorders). In addition to an analysis of the best in evidence-based practice and research, the volume also includes brief clinical vignettes to help present the material in an easily accessible, understandable, readable, and relevant format. The chapter authors are experts in the treatment of these disorders and review a wide variety of empirically supported treatments for children, adolescents, and adults.

Family Therapy as an Alternative to Medication critically and passionately explores the concepts and practices that constitute the interface between family systems based psychotherapy and modern biological psychiatry. This diverse collection of essays, eight by psychiatrists, is neither for nor against medication, but takes a skeptical view of the unquestioned dominance that medication-based treatments have achieved among mental health practitioners. Its viewpoint is that therapeutic attention to context and relationships, regularly diminished when medications are prescribed, interferes with the development of psychiatric disorders, adds to maturity, and expands consciousness. Clinical examples, by both practitioners and patients, are used to define potential problems that arise from trying to combine a medical model with family systems work and also illustrate the decision-making processes and methods for applying family systems based therapies. This book will stimulate thoughtful conversation among students and practitioners of all mental health disciplines.

Cognitive Behavioral Therapy for Preventing Suicide Attempts consolidates the accumulated knowledge and efforts of leading suicide researchers, and describes how a common, cognitive behavioral model of suicide has resulted in 50% or greater reductions in suicide attempts across clinical settings. Simple and straightforward descriptions of these techniques are provided, along with clear explanations of the interventions' rationale and scientific support. Critically, specific adaptations of these interventions designed to meet the demands and needs of diverse settings and populations are explained. The result is a practical, clinician-friendly, how-to guide that demonstrates how to effectively reduce the risk for suicide attempts in any setting.

Treating Disruptive Disorders is a practical book for busy clinicians-psychiatrists, psychologists, mental health counselors, clinical social workers, and more-as well as students, interns, or residents in the mental health professions. It distills the most important information about combined as well as solitary treatments of a variety of psychological disorders characterized by disruptive behaviors, including those where disruptive aspects are part of core symptoms (like ADHD, ODD, or conduct disorder), and those where disruptive features are commonly associated with core symptoms (like mood, personality, and cognitive/developmental disorders). In addition to an analysis of the best in evidence-based practice and research, the volume also includes brief clinical vignettes to help present the material in an easily accessible, understandable, readable, and relevant format. The chapter authors are experts in the treatment of these disorders and review a wide variety of empirically supported treatments for children, adolescents, and adults.

A single source for accurate scientific information on herbal remedies! This comprehensive handbook (comprised of two volumes of 700+ pages each) provides a snapshot of 160 herbal products that have been tested in clinical trials. Details of the products and the clinical trials they underwent are here in an easy-to-read, at-a-glance format. Each botanical profile in The Handbook of Clinically Tested Herbal Remedies contains a summary section (table, text and references), followed by product information and clinical trials for that particular product. An evaluation of the strength of the evidence from the trials, along with the context for therapeutics is included to give you a complete picture of each remedy and its usefulness or lack thereof. If there is more than one product based on a particular botanical then the trials are grouped according to the product. This valuable book also makes purchasing easy with manufacturer contact information. With over 30 individual botanicals and 10 multi-ingredient formulas, 160 products and 360 clinical studies, The Handbook of Clinically Tested Herbal Remedies is the book you need to make an informed selection of herbal products. Not only does it list proprietary herbal products that have been tested in controlled clinical studies and provide a rating of the quality of those trials, but, it also describes the fundamentals of herbal medicine, including regulation, characterization, standardization, bioavailability, efficacy, safety, pharmacopoeial monographs as well as incentives, or lack of incentive, for US and European manufacturers to conduct clinical studies. Contributors to the chapters describing the fundamentals of herbal medicine include: * the late Dr. Varro Tyler, Distinguished Professor Emeritus at Purdue University and co-author of Tyler's Honest Herbal, Rational Phytotherapy, and Tyler's Herbs of Choice * Loren Israelsen, JD, president of the LDI group * Tieraona Low Dog, MD, Chair of the USP Dietary Supplement Information Committee * Joerg Grunwald, PhD, co-author of the Physicians Desk Reference (PDR) for Herbal Medicines, and Stefan Spiess, RPh, President of Grunwalder GmbH * Anton Biber, PhD, and Friedrich Lang, PhD, experts in the bioavailability of herbal medicine at Dr. Willmar Schwabe GmbH & Co., Germany * Anthony Almada, MSc, founder and Chief Scientific Officer of IMAGINutrition, Inc. * Joseph M. Betz, PhD, Director of the Dietary Supplements Methods and Reference Materials Program at the NIH Office of Dietary Supplements * Ezra Bejar, PhD, president of Plant Bioassay * Uwe Koetter, PhD, Director of New OTC and Dietary Supplement Product Development at GlaxoSmithKline * Srini Srinivasan, PhD, Vice President of the Dietary Supplement Verification Program of the United States Pharmacopeia (USP) * Roy Upton, Executive Director of the American Herbal Pharmacopoeia. All of the clinical trials in The Handbook of Clinically Tested Herbal Remedies were rated as to their Level of Evidence according to a system designed by Tieraona Low Dog, MD, Chair of the United States Pharmacopoeia Dietary Supplements/Botanicals Expert Panel and a member of the White House Commission on Complementary and Alternative Medicine. The reviewers of the clinical trials included Karriem Ali, MD; Richard Aranda, MD; Elliot Fagelman, MD; Mary Hardy, MD; David Heber, MD, PhD, FACP, FACN; John Trimmer Hicks, MD, FACP, FACR; Hannah Kim, MD; Franklin C. Lowe, MD, MPH; Richard D. O'Connor, MD; Barry S. Oken, M.D; Lynn Shinto, ND; and Keith Wesnes, PhD.

The British Pharmacopoeia has provided official standards for the quality of substances, medicinal products and articles used in medicine since its first publication in 1864. It is used in over 100 countries and remains an essential global reference in pharmaceutical research and development and quality control. This book explores how these standards have been achieved through a comprehensive review of the history and development of the pharmacopoeias in the UK, from the early London, Edinburgh and Dublin national pharmacopoeias to the creation of the British Pharmacopoeia and its evolution over 150 years. Trade in medicinal substances and products has always been global, and the British Pharmacopoeia is placed in its global context as an instrument of the British Empire as it first sought to cover the needs of countries such as India and latterly as part of its role in international harmonisation of standards in Europe and elsewhere. The changing contents of the pharmacopoeias over this period reflect the changes in medical practice and the development of dosage forms from products dispensed by pharmacists to commercially manufactured products, from tinctures to the latest monoclonal antibody products. The book will be of equal value to historians of medicine and pharmacy as to practitioners of medicine, pharmacy and pharmaceutical analytical chemistry.

First isolated as a chemical compound by a Russian chemist in 1866, dimethyl sulfoxide (DMSO) proved to be a near-perfect solvent for decades before its remarkable biological and medical activities were discovered. DMSO is one of the most prodigious agents ever to come out of the world of drug development. Its wide range of biological actions involving plants, animals, and humans has led to the publication of tens of thousands of articles in the scientific literature. Dimethyl Sulfoxide (DMSO) in Trauma and Disease examines the major clinical uses of DMSO in humans as supported by basic evidence derived from experiments in animals, including its effects in disorders such as osteoarthritis, interstitial cystitis, gastrointestinal inflammatory changes, scleroderma, respiratory distress, myasthenia gravis, cardiac disease, traumatic brain injury, and Alzheimer's disease. The effects of DMSO on pain, cancer, stroke, and spinal cord injury are also discussed. The book explores how its chemical structure is able to react and deactivate toxic molecules generated by DNA damage, free radical formation, inflammation, oxidation, and infection. For the first time, the collective data on the biological, chemical, and medical actions of DMSO are presented and analyzed from the published scientific literature. Clearly written, the book incorporates easy-to-understand scientific descriptions that appeal both to health care professionals and the millions of people worldwide who have used DMSO for an assortment of ailments as a prescriptive or off-label medication.

With a high diversity of vegetation in Iran, over 8000 plant species are in existence. More than 2300 species of these plants have medicinal, edible and industrial properties, and more than 1700 species of them are endemic. Natural Products and Botanical Medicines of Iran provides an overview on important endemic plants and their usages. All results have been tabulated and key detailed information of each species is presented with background data. Features: Provides an understanding of indigenous plant-derived natural medicines of the most important medicinal plants in the region Includes discussions and critical views on the potentials and challenges for further development of the selected plants in a modern setting Details the important plants and sets out the chapters based on either taxonomy or medical use